Congenica to provide Tertiary Analysis for Whole Genome Sequencing for Hong Kong Genome Project
Congenica selected to provide tertiary analysis for whole genome sequencing services for the Hong Kong Genome Project (HKGP).
Congenica and IAB Agree to Distribution Deal in Central Europe
Congenica forms a strategic partnership with Institute of Applied Biotechnologies (IAB) as a distributor for Czech Republic, Slovakia, Hungary and Poland.
Congenica launches Comprehensive Genetic Carrier Screening at Arab Health 2022
Congenica launches service at Arab Health that creates combined digital genomic profiles from parents for comprehensive carrier screening.
Congenica Expands its Clinical Consulting Services
Congenica has launched a new “sample to report” service, providing additional access to sequence providers when labs have limited sequencing capacity.
Congenica named as genomic analysis platform in ‘Impact of the 100,000 Genomes Pilot – Preliminary Report’ in the New England Journal of Medicine
Congenica named in Impact of the 100k Genomes Pilot on rare disease diagnosis in healthcare publication in the New England Journal of Medicine
Congenica is Joint Winner of MIT Solve The Horizon Prize
Congenica is announced as a joint winner of MIT Solve Horizon Prize
Congenica announced as a finalist for MIT Solve’s Horizon Prize
Congenica has been selected as a finalist for the prestigious Horizon Prize, powered by MIT Solve.
Congenica signs distribution agreement with ATC Healthcare in Turkey
Congenica announces new distribution agreement with ATC Healthcare, a Turkish business investing in advanced tech in molecular diagnosis & life sciences.
Congenica Receives CE Mark for Genomic Analysis Software
Congenica NGS data analysis software for genomic data interpretation is now CE marked under the In Vitro Diagnostics Directive.
David Atkins welcomes the Government's Life Sciences Sector Vision
A press release from the UK Bio Industry Association (BIA) welcomes the Government's new Life Sciences Sector Vision and quotes Congenica CEO David Atkins
Clinical OMICs interview with David Atkins CEO Congenica
Clinical OMICs features an interview with Congenica CEO David Atkins who talks about the genomic medicine landscape and Congenica's plans for the future.
Congenica funded to reduce fatal drug interactions by mapping genes
New software to reduce the number of adverse drug reactions is being developed thanks to a joint investment of £2 million provided by UKRI and L& G.